4Annemans L, Brignone M, Druais S.Cost-effeetiveness analysis of pharmaceutical treatment options in the first-line management of major depressive disorder in Belgium [J]. PharmacoEeonomies, 2014,32(5) :479-93.
5Demyttenaere K, Hemels ME, Hudry J, ~. A cost-effectiveness model of escitalopram, eitalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium [J].Clinical Therapeutics, 2005,27(1) : 111-24.
6Wessling A, Ramsberg J.The review of antidepressants: the Den- tal and Pharmaceutical Bene?ts Agency.Solna:TLV.2008.
